Perez, D., Sharples, K.J., Broom, R., Jeffery, M., Proctor, J., Hinder, V., . . . Findlay, M. (2015). A randomised phase IIb trial to assess the efficacy of ReCharge ice cream in preventing chemotherapy-induced diarrhoea. Supportive Care in Cancer, 23, 3307–3315.
To assess the efficacy of ReCharge ice cream in reducing the number of days with chemotherapy-induced diarrhea (CID)
Eligible patients were randomized 1:1 to ReCharge or placebo, administered as one 11 g placebo serving or ReCarge daily for 10–18 days prechemotherapy and continued for six weeks from the start of chemotherapy.
The mean number of days with CID was not statistically significant on ReCharge versus placebo. There were no statistically significant differences between the treatment arms.
The study did not demonstrate effectiveness of ReCharge in reducing diarrhea.
ReCharge is not effective in CID management.